Anti-SSA/SSB-negative Sjögren's syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution

Autoimmunity Reviews

Volumn 14, Issue 11, 2015, Pages 1019-1022

  Quartuccio, Luca ^a   Baldini, Chiara ^b   Bartoloni, Elena ^c   Priori, Roberta ^d   Carubbi, Francesco ^e   Corazza, Laura ^a   Alunno, Alessia ^c   Colafrancesco, Serena ^d   Luciano, Nicoletta ^b   Giacomelli, Roberto ^e   Gerli, Roberto ^c   Valesini, Guido ^d   Bombardieri, Stefano ^b   De Vita, Salvatore ^a  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

B cell; Lymphoma; Rheumatoid factor; Sj gren's syndrome

Indexed keywords

CRYOGLOBULIN; LA ANTIBODY; RHEUMATOID FACTOR; RO ANTIBODY;

ADULT; AGE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERGAMMAGLOBULINEMIA; IMMUNOGLOBULIN BLOOD LEVEL; LEUKOPENIA; LOW RISK PATIENT; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; ONSET AGE; PREVALENCE; PURPURA; RAYNAUD PHENOMENON; REVIEW; SALIVARY GLAND BIOPSY; SIALOADENITIS; SJOEGREN SYNDROME; BIOPSY; COMPLICATION; IMMUNOLOGY; LYMPHOPROLIFERATIVE DISORDERS; PATHOLOGY; RISK FACTOR; SJOGREN'S SYNDROME;

BIOPSY; HUMANS; LYMPHOMA; LYMPHOPROLIFERATIVE DISORDERS; PREVALENCE; RISK FACTORS; SJOGREN'S SYNDROME;

EID: 84941259893     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.07.002     Document Type: Review

References (27)

1. Tzioufas A.G., Kapsogeorgou E.K., Moutsopoulos H.M. Pathogenesis of Sjögren's syndrome: what we know and what we should learn. J Autoimmun 2012, 39(1-2):4-8.
2. Baldini C., Pepe P., Quartuccio L., Priori R., Bartoloni E., Alunno A., et al. Primary Sjogren's syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. Rheumatology (Oxford) 2014, 53(5):839-844.
3. Ramos-Casals M., Brito-Zerón P., Solans R., Camps M.T., Casanovas A., Sopeña B., et al. SS Study Group; Autoimmune Diseases Study Group (GEAS) of the Spanish Society of Internal Medicine (SEMI). Systemic involvement in primary Sjögren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). Rheumatology (Oxford) 2014, 53(2):321-331.
4. Burbelo P.D., Ambatipudi K., Alevizos I. Genome-wide association studies in Sjögren's syndrome: what do the genes tell us about disease pathogenesis?. Autoimmun Rev 2014, 13(7):756-761.
5. Ramos-Casals M., Brito-Zerón P., Kostov B., Sisó-Almirall A., Bosch X., Buss D., et al. Google-driven search for big data in autoimmune geoepidemiology: analysis of 394,827 patients with systemic autoimmune diseases. Autoimmun Rev 2015, 14(8):670-679.
6. Vitali C., Bombardieri S., Jonsson R., Moutsopoulos H.M., Alexander E.L., Carsons S.E., et al. European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002, 61(6):554-558.
7. Brito-Zerón P., Kostov B., Solans R., Fraile G., Suárez-Cuervo C., Casanovas A., et al. on behalf of the SS Study Group, Autoimmune Diseases Study Group (GEAS), Spanish Society of Internal Medicine (SEMI). Systemic activity and mortality in primary Sjögren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients. Ann Rheum Dis 2014, [Epub ahead of print]. 10.1136/annrheumdis-2014-206418.
8. Gottenberg J.E., Busson M., Cohen-Solal J., Lavie F., Abbed K., Kimberly R.P., et al. Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjögren's syndrome. Ann Rheum Dis 2005, 64(7):1050-1055.
9. Carubbi F., Alunno A., Cipriani P., Bartoloni E., Baldini C., Quartuccio L., et al. A retrospective, multicenter study evaluating the prognostic value of minor salivary gland histology in a large cohort of patients with primary Sjögren's syndrome. Lupus 2015, 24(3):315-320.
10. Quartuccio L., Isola M., Baldini C., Priori R., Bartoloni E., Carubbi F., et al. Clinical and biological differences between cryoglobulinaemic and hypergammaglobulinaemic purpura in primary Sjögren's syndrome: results of a large multicentre study. Scand J Rheumatol 2015, 44(1):36-41.
11. Quartuccio L., Isola M., Baldini C., Priori R., Bartoloni Bocci E., Carubbi F., et al. Biomarkers of lymphoma in Sjögren's syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. J Autoimmun 2014, 51:75-80.
12. Ekström Smedby K., Vajdic C.M., Falster M., Engels E.A., Martínez-Maza O., Turner J., et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 2008, 111(8):4029-4038.
13. Giannouli S., Voulgarelis M. Predicting progression to lymphoma in Sjögren's syndrome patients. Expert Rev Clin Immunol 2014, 10(4):501-512.
14. Nocturne G., Mariette X. Sjögren syndrome-associated lymphomas: an update on pathogenesis and management. Br J Haematol 2015, 168(3):317-327.
15. Jonsson M.V., Theander E., Jonsson R. Predictors for the development of non-Hodgkin lymphoma in primary Sjögren's syndrome. Presse Med 2012, 41(9 Pt 2):e511-e516.
16. Voulgarelis M., Moutsopoulos H.M. Mucosa-associatedlymphoidtissuelymphoma in Sjögren's syndrome: risks, management, and prognosis. Rheum Dis Clin North Am 2008, 34(4):921-933. [viii].
17. Theander E., Vasaitis L., Baecklund E., Nordmark G., Warfvinge G., Liedholm R., et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome. Ann Rheum Dis 2011, 70(8):1363-1368.
18. Carubbi F., Alunno A., Cipriani P., Di Benedetto P., Ruscitti P., Berardicurti O., et al. Is minor salivary gland biopsy more than a diagnostic tool in primary Sjögren[U+05F3]s syndrome? Association between clinical, histopathological, and molecular features: a retrospective study. Semin Arthritis Rheum 2014, 44(3):314-324.
19. De Re V., De Vita S., Gasparotto D., Marzotto A., Carbone A., Ferraccioli G., et al. Salivary gland B cell lymphoproliferative disorders in Sjögren's syndrome present a restricted use of antigen receptor gene segments similar to those used by hepatitis C virus-associated non-Hodgkins's lymphomas. Eur J Immunol 2002, 32(3):903-910.
20. Ramos-Casals M., Cervera R., Font J., García-Carrasco M., Espinosa G., Reino S., et al. Young onset of primary Sjögren's syndrome: clinical and immunological characteristics. Lupus 1998, 7(3):202-206.
21. Haga H.J., Jonsson R. The influence of age on disease manifestations and serological characteristics in primary Sjögren's syndrome. Scand J Rheumatol 1999, 28(4):227-232.
22. Papageorgiou A., Mavragani C.P., Nezos A., Zintzaras E., Quartuccio L., De Vita S., et al. A B-cell activating factor receptor (BAFF-R) His159Tyr mutation in Sjögren's Syndrome related lymphoproliferation. Arthritis Rheumatol Jun 19 2015, 10.1002/art.39231.
23. Gottenberg J.E., Cinquetti G., Larroche C., Combe B., Hachulla E., Meyer O., et al. Club Rhumatismeset Inflammations and the French Society of Rheumatology. Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis 2013, 72(6):1026-1031.
24. Devauchelle-Pensec V., Mariette X., Jousse-Joulin S., Berthelot J.M., Perdriger A., Puéchal X., et al. Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Ann Intern Med 2014, 160(4):233-242.
25. Mariette X., Seror R., Quartuccio L., Baron G., Salvin S., Fabris M., et al. Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis 2015, 74(3):526-531.
26. De Vita S., Quartuccio L., Seror R., Salvin S., Ravaud P., Fabris M., et al. Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the beliss open-label phase II study. Ann Rheum Dis 2015, 74(Suppl2):338.
27. Brito Zeron P., Kostov B.A., Zeher M., Theander E., Gottenberg J.E., Baldini C., et al. Big Data Sjögren Project (EULAR-SS Task Force International Network): characterization t diagnosis of 5027 patients with primary Sjögren syndrome. Ann Rheum Dis 2015, 74(Suppl. 2):102.